ReviewRheumatology international2020
Coronavirus disease 2019 (COVID-19) in a patient with ankylosing spondylitis treated with secukinumab: a case-based review.
Review in Rheumatology international, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 32 citations in OpenAlex.
- Weathering the Storm: How Age and Biologics Influence the COVID-19 Cytokine Surge.Pathogens (Basel, Switzerland) · 2025Review
- Predictive Factors for COVID-19 Severity in Patients with Axial Spondyloarthritis: Real-World Data from the Romanian Registry of Rheumatic Diseases.Medicina (Kaunas, Lithuania) · 2025Observational
- COVID-19: A Disease Driven by Protease/Antiprotease Imbalance? A Specific Review Five Years into the Pandemic.Infection and drug resistance · 2025Review
- CAse-BAsed REview sTandards (CABARET): Considerations for Authors, Reviewers, and Editors.Journal of Korean medical science · 2024Review
- COVID-19 disease and autoimmune disorders: A mutual pathway.World journal of methodology · 2022Review
- Axial spondyloarthritis may protect against poor outcomes in COVID-19: propensity score matched analysis of 9766 patients from a nationwide multi-centric research network.Clinical rheumatology · 2022Article
- Evidence for the Use of Secukinumab in Patients with Radiographic and Non-radiographic Axial Spondyloarthritis in the Last 5 Years.Rheumatology and therapy · 2022Review
- [Effects of the COVID-19 pandemic on a cohort of patients with vein occlusion].Revista clinica espanola · 2021Article
- Article
- Interleukin-17A (IL-17A): A silent amplifier of COVID-19.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2021Article
- Attitudes of patients with a rheumatic disease on drug use in the COVID-19 pandemic.Advances in rheumatology (London, England) · 2021Article
- Rheumatological complications of Covid 19.Autoimmunity reviews · 2021Review
- Secukinumab in severe COVID-19 pneumonia: Does it have a clinical impact?The Journal of infection · 2021Article
- Postdischarge rheumatic and musculoskeletal symptoms following hospitalization for COVID-19: prospective follow-up by phone interviews.Rheumatology international · 2021Article
- Population-level interest in anti-rheumatic drugs in the COVID-19 era: insights from Google Trends.Clinical rheumatology · 2021Article
- Reduced frequency of T helper 17 and T helper 1 cells and their association with critical coronavirus disease 2019.APMIS : acta pathologica, microbiologica, et immunologica Scandinavica · 2021Article
- COVID-19 illness and autoimmune diseases: recent insights.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2021Review
- The course of COVID-19 infection and prolonged sneezing and nasal congestion in a patient using ixekizumab.Dermatologic therapy · 2021Article
- Public interest in rheumatic diseases and rheumatologist in the United States during the COVID-19 pandemic: evidence from Google Trends.Rheumatology international · 2021Observational
- Comorbidities in rheumatic diseases need special consideration during the COVID-19 pandemic.Rheumatology international · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Severe acute respiratory syndrome coranovirus-2 (SARS-CoV-2) infection has become an important health-care issue worldwide. The coronavirus disease 2019 (COVID-19) has also raised concerns among patients with inflammatory rheumatic conditions and their treating physicians. There are emerging data regarding the potential risks of SARS-CoV-2 for this particular patient group. However, less is known with regard to the course of COVID-19 among patients receiving IL-17 inhibitors. The aim of the current article is to review the growing body of knowledge on the course/management of COVID-19 in patients with inflammatory rheumatic diseases by presenting a SARS-CoV-2 infected case with ankylosing spondylitis under secukinumab therapy. A 61-year old patient with ankylosing spondylitis who was on secukinumab therapy for 5 months admitted with newly onset fever and gastrointestinal complaints. After being hospitalized, she developed respiratory manifestations with focal pulmonary ground-glass opacities and multiple nodular densities in both lungs. The patient was tested positive for SARS-CoV-2 infection. Substantial clinical improvement was obtained following a management plan, which included tocilizumab, hydroxychloroquine, prednisolone and enoxaparin sodium. PubMed/MEDLINE and Scopus databases were searched by using relevant keywords and their combinations. The literature search revealed four articles reporting the clinical course of COVID-19 in seven rheumatic patients on secukinumab. The clinical course of SARS-CoV-2 infection was mild in most of these patients, while one of them experienced severe COVID-19. Interleukin-17 has been related to the hyperinflammatory state in COVID-19 and IL-17 inhibitors were presented as promising targets for the prevention of aberrant inflammation and acute respiratory distress in COVID-19. However, this hypothesis still remains to be proved. Further studies are warranted in order to test the benefits and risks of IL-inhibitors in SARS-CoV-2 infected individuals.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.